Hosted on MSN4d
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial
Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a ...
ophthalmologytimes5d
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...
manilatimes6d
Bitget Wallet Supports Jupiter's JUP Airdrop, Eligibility Checker Now Live
To participate, users can access the Jupiter Airdrop Checker directly within the Bitget Wallet app's Discover section. By ...
Ocugen announces first patient dosed in Phase 1 OCU200 trial for DME
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...